Latest

Jul 18, 2018
The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
Jul 18, 2018
Alison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.
Jul 17, 2018
When design thinking is incorporated into the business model, pharmaceutical businesses can truly differentiate themselves and recognize a valuable impact, writes Adam Taicher.
Jul 13, 2018
Pharmaceutical Executive
Outlining a real-world case study in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Jul 13, 2018
Pharmaceutical Executive
The role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).
Jul 10, 2018
Pharmaceutical Executive
PharmExec talks to Dr. Gil Van Bokkelen, co-founder of Athersys, a company looking to forge new advances in the stem cell arena.
Jul 03, 2018
Pharmaceutical Executive
The importance of early development strategy and planning for biologic patent term extension.
Jul 02, 2018
Jill Wechsler details recent bipartisan action to support treatment of opioid abusers and deter inappropriate drug prescribing and illegal distribution.
Jun 25, 2018
FDA has finalized a more flexible policy for how biopharma companies discuss payments, outcomes, and healthcare economic data with payers, formulary committees, and other audiences with expertise in drug prescribing and coverage.
Jun 25, 2018
Steve Gens talks to Pharm Exec about the evolution of Regulatory Information Management (RIM) and offers some predictions for 2022.
native1_300x100
lorem ipsum